Resistance to imatinib: mutations and beyond.

  title={Resistance to imatinib: mutations and beyond.},
  author={Paul La Ros{\'e}e and Michael Werner Nikolaus Deininger},
  journal={Seminars in hematology},
  volume={47 4},
Mechanisms of resistance to the tyrosine kinase inhibitor (TKI) imatinib had been modeled in vitro even prior to the first reports of clinical resistance in patients with chronic myeloid leukemia (CML). The discovery that BCR-ABL is reactivated at the time of resistance and the unveiling of point mutations within the kinase domain of BCR-ABL as a major resistance mechanism have driven the development of second-generation TKIs. These agents are effective in a significant proportion of patients… CONTINUE READING